Recruiting Cardiomyopathy Studies in Houston
Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy
The purpose of this study is to evaluate the safety and effectiveness of an experimental drug called human allogeneic mesenchymal stem cell therapy....
Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM
This is a first-in-human, non-randomized, open-label study designed to evaluate the safety, tolerability, and pharmacodynamics (PD) of TN-201 in adult patients with symptomatic hypertrophic cardiomyop...
About Cardiomyopathy Clinical Trials in Houston
Cardiomyopathy refers to diseases of the heart muscle that make it harder for the heart to pump blood. Types include dilated, hypertrophic, and restrictive cardiomyopathy. Treatment depends on the type and may include medications, devices, or heart transplant.
There are currently 2 cardiomyopathy clinical trials recruiting participants in Houston, TX. These studies are seeking a combined 166 participants. Research is being sponsored by Joshua M Hare, Tenaya Therapeutics. Clinical trial participation is free and participants receive study-related medical care at no cost.
Cardiomyopathy Clinical Trials in Houston — FAQ
Are there cardiomyopathy clinical trials in Houston?
Yes, there are 2 cardiomyopathy clinical trials currently recruiting in Houston, TX. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Houston?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Houston research site will contact you about next steps.
Are clinical trials in Houston free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Houston studies also compensate for your time and travel.
What cardiomyopathy treatments are being tested?
The 2 active trials in Houston are testing new therapies including novel drugs, biologics, and treatment approaches for cardiomyopathy.
Data updated March 2, 2026 from ClinicalTrials.gov